Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert C Goldman

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Future Medicinal Chemistry|March 24, 2011
Maximizing bactericidal activity with combinations of bioreduced drugsRobert C Goldman
Infectious Disorders Drug Targets|December 7, 2018
Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChemRobert C Goldman
Tuberculosis (Edinburgh, Scotland)|October 15, 2013
Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?Robert C Goldman
Current Drug Targets. Infectious Disorders|September 24, 2004
The macrolide-bacterium interaction and its biological basisRobert C Goldman, Franco Scaglione
Tuberculosis (Edinburgh, Scotland)|September 1, 2009
Discovery and validation of new antitubercular compounds as potential drug leads and probesRobert C Goldman, Barbara E Laughon
Infectious Disorders Drug Targets|November 1, 2007
The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global controlRobert C Goldman, Kevin V Plumley, Barbara E Laughon
Infectious Disorders Drug Targets|April 8, 2011
Quinoxaline 1,4-di-N-oxide and the potential for treating tuberculosisEsther Vicente, Raquel Villar, Silvia Pérez-Silanes, et al.
Microbiology (Reading, England)|February 1, 1997
Phenotype in Candida albicans of a disruption of the BGL2 gene encoding a 1,3-beta-glucosyltransferaseAparna V Sarthy, Thomas McGonigal, Michael Coen, et al.
Microbiology (Reading, England)|December 2, 2000
Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylaseEugene R Baizman, Arthur A Branstrom, Clifford B Longley, et al.
The Journal of Antimicrobial Chemotherapy|May 27, 2008
In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxideRaquel Villar, Esther Vicente, Beatriz Solano, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Future Medicinal Chemistry|March 24, 2011
Maximizing bactericidal activity with combinations of bioreduced drugsRobert C Goldman
Infectious Disorders Drug Targets|December 7, 2018
Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChemRobert C Goldman
Tuberculosis (Edinburgh, Scotland)|October 15, 2013
Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis?Robert C Goldman
Current Drug Targets. Infectious Disorders|September 24, 2004
The macrolide-bacterium interaction and its biological basisRobert C Goldman, Franco Scaglione
Tuberculosis (Edinburgh, Scotland)|September 1, 2009
Discovery and validation of new antitubercular compounds as potential drug leads and probesRobert C Goldman, Barbara E Laughon
Infectious Disorders Drug Targets|November 1, 2007
The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global controlRobert C Goldman, Kevin V Plumley, Barbara E Laughon
Infectious Disorders Drug Targets|April 8, 2011
Quinoxaline 1,4-di-N-oxide and the potential for treating tuberculosisEsther Vicente, Raquel Villar, Silvia Pérez-Silanes, et al.
Microbiology (Reading, England)|February 1, 1997
Phenotype in Candida albicans of a disruption of the BGL2 gene encoding a 1,3-beta-glucosyltransferaseAparna V Sarthy, Thomas McGonigal, Michael Coen, et al.
Microbiology (Reading, England)|December 2, 2000
Antibacterial activity of synthetic analogues based on the disaccharide structure of moenomycin, an inhibitor of bacterial transglycosylaseEugene R Baizman, Arthur A Branstrom, Clifford B Longley, et al.
The Journal of Antimicrobial Chemotherapy|May 27, 2008
In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxideRaquel Villar, Esther Vicente, Beatriz Solano, et al.
Pageof 2